128 He J et al. / Triple negative breast cancer Acknowledgment This study was supported by Science and Technology Program of Guangdong Province (NO.73125) and Key Science and Technology Program of Shenzhen City (NO.200801004). References 1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-8. 2. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44. 3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363: 1938-48. 4. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer – prognostic factors and survival. Radiol Oncol 2011; 45: 46-52. 5. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32. 6. Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, et al. Triple- negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 2010; 17(Suppl 3): 384-90. 7. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP- Ribose) polymerase inhibition: “Targeted” therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16: 4702-10. 8. Wang XM, He JS, Tong JM. Clinical application of preoperative superselec- tive intra-arterial chemotherapy in the treatment of late breast cancer cases. Journal of Surgery Concepts & Practice 2006; 11: 136-8. 9. Zuo WS. Modern molecular oncology of breast cancer. 2nd edition. Shandong: Shandong Science & Technology Press; 2006. p. 974-9. 10. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in differ- ent biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-40. 11. Yi SY, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, et al. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer 2010; 10: 527. 12. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19: 617-21. 13. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer sub- types. Clin Cancer Res 2007; 13: 2329-34. 14. Maegawa RO, Tang SC. Triple-negative breast cancer: unique biology and its management. Cancer Invest 2010; 28: 878-83. 15. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8. 16. Maurer CA, Borner M, Buchler MW. Regional chemotherapy of gastro- intestinal cancer. Digestive Surg 1997; 14: 9-22. 17. Miura T, Takeuchi I, Kikuoka S, Miura T. Intra-arterial infusion chemotherapy for advanced breast cancer – 5 cases of marked response. Gan To Kagaku Ryoho 2009; 36: 2108-10. 18. Vanel D. Interventional radiology: the new daily work of the breast radiolo- gist. Eur J Radiol 2002; 42: 1. Radiol Oncol 2011; 45(2): 123-128. 19. Pacetti P, Mambrini A, Paolucci R, Sanguinetti F, Palmieri B, Della Seta R, et al. Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer. In Vivo 2006; 20: 761-4. 20. Takizawa K, Shimamoto H, Ogawa Y, Yoshimatsu M, Yagihashi K, Nakajima Y, et al. Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an im- planted catheter-port system after redistribution of arterial tumor supply. Cardiovasc Inter Rad 2009; 32: 1059-66.